Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
European market sits at the center of this dementia and brain health question.
Yes, European market access for investigational Alzheimer’s drugs has hit significant delays in 2025-2026, with multiple promising treatments facing rejection or withdrawal from regulatory consideration. Most notably, Eli Lilly’s Kisunla (donanemab)—a monthly injection for mild cognitive impairment and early dementia—was not recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, citing concerns that potential benefits do not outweigh serious side effects, including fatal brain swelling. In the same regulatory environment, Anavex Life Sciences withdrew its European Union marketing authorization application for blarcamesine on March 25, 2026, after receiving negative feedback from the Committee for Herbal Medicinal Products, effectively ending that particular treatment pathway in Europe.
These setbacks reflect a fundamental tension in Alzheimer’s treatment: drugs that may slow cognitive decline for some patients also carry real risks of brain inflammation and swelling that can be life-threatening. European regulators are taking a notably cautious approach compared to their U.S. counterparts, insisting on stronger evidence of safety before approval. For families in Europe seeking newer treatment options, this means fewer alternatives at the pharmacy and longer waits for medications that might help.
Table of Contents
- Why Are European Regulators Rejecting Alzheimer’s Drugs More Strictly Than the FDA?
- The Specific Cases of Blarcamesine and Kisunla—What Went Wrong?
- Safety Concerns—Why Brain Swelling and Bleeding Matter More Than Efficacy Data
- The Path Forward for Patients and Families in Europe—What Treatment Options Remain?
- How Regulatory Delays Affect Clinical Practice and Treatment Planning
- What About Other Alzheimer’s Drugs in the Development Pipeline?
- Looking Forward—What the European Regulatory Delays Mean for the Future of Dementia Care
- Conclusion
Why Are European Regulators Rejecting Alzheimer’s Drugs More Strictly Than the FDA?
The European Medicines Agency (EMA) and the Food and drug Administration (FDA) have diverged sharply on Alzheimer’s approvals over the past two years. The FDA granted accelerated approval to lecanemab (Leqembi) in January 2023, while the EMA initially rejected it in July 2024, only later recommending conditional approval in November 2024 after additional data was submitted. Even then, in January 2025, the European Commission requested further review of safety information before issuing a final decision. This regulatory caution isn’t arbitrary—it stems from Europe’s risk-benefit framework, which requires clearer evidence that benefits substantially outweigh harms before approval. The EMA’s stance reflects lessons learned from previous drug approvals that were later restricted or withdrawn when safety issues emerged.
European regulators have also historically held higher evidentiary standards for neurological medications, particularly those affecting the central nervous system. For Kisunla specifically, the committee raised concerns about amyloid-related imaging abnormalities (ARIA)—brain inflammation visible on MRI—which can lead to serious complications including fatal brain swelling in a small but measurable percentage of patients. The EMA wanted to see a more favorable safety profile before recommending the drug to millions of patients across the EU. This regulatory conservatism has real consequences. Patients and families in Europe have fewer options for newly approved treatments, and pharmaceutical companies may deprioritize European development programs if approval pathways appear too uncertain. It also creates a divide where a drug approved and available in the United States may remain inaccessible in neighboring European countries for months or years.
The Specific Cases of Blarcamesine and Kisunla—What Went Wrong?
Anavex Life Sciences’ withdrawal of blarcamesine from European consideration represents one route to delayed access: the company simply decided the regulatory path was not viable. Blarcamesine was being evaluated as an add-on therapy for early Alzheimer’s disease in adults, with some preliminary data suggesting cognitive benefits. However, after the Committee for Herbal Medicinal Products provided negative feedback indicating they would not issue a positive opinion, Anavex withdrew the application in March 2026 rather than risk a formal rejection. This decision, while financially rational for the company, effectively removes that treatment option from European patients indefinitely. Eli Lilly’s Kisunla took a different but equally disappointing path. The CHMP recommended against approval, explicitly stating that risks outweighed potential benefits.
Kisunla is administered as a monthly injection, which would have been a practical advantage over weekly infusions like lecanemab. The drug showed some efficacy in slowing cognitive decline in people with mild cognitive impairment and mild dementia due to Alzheimer’s disease—but at a cost. brain swelling (ARIA-E) and microhemorrhages (ARIA-H) occurred in trial participants, and while most cases resolved, some were severe or fatal. The EMA committee determined that this safety profile was unacceptable for approval in Europe, even though the FDA had previously approved similar agents with comparable side effect profiles. The European Commission has 67 days from the CHMP’s opinion to provide a formal regulatory decision on Kisunla. However, given the committee’s explicit non-recommendation, approval appears unlikely. This timeline matters for patients and clinicians hoping for new options—67 days of waiting for a decision that may have already been effectively made.
Safety Concerns—Why Brain Swelling and Bleeding Matter More Than Efficacy Data
Amyloid-related imaging abnormalities represent the central safety issue driving European regulatory caution around anti-amyloid monoclonal antibodies like Kisunla and lecanemab. These drugs work by clearing amyloid plaques from the brain, but the cleanup process itself can trigger inflammation. Some patients develop visible brain swelling (ARIA-E) or microhemorrhages (ARIA-H) on MRI scans. While many cases are asymptomatic—visible on imaging but causing no symptoms—others result in headaches, confusion, vision changes, or in the most severe cases, fatal swelling. In clinical trials, ARIA occurred in 10-15% of treated patients, compared to 2-5% in placebo groups.
The absolute numbers may sound small, but when applied to millions of elderly European patients, even rare adverse events become significant public health concerns. The EMA committee weighed this carefully: if 2 million European patients with Alzheimer’s were treated with Kisunla, how many would experience serious brain swelling? How many would die? The committee concluded the risk was too high relative to the modest cognitive benefit demonstrated in trials. Notably, patients on these drugs must undergo regular MRI monitoring to catch asymptomatic ARIA before it becomes symptomatic—an additional burden of testing and cost that European healthcare systems would need to absorb. A critical limitation in the approval debate is that amyloid reduction doesn’t always translate to meaningful functional improvement in daily life. Trials show slowing of cognitive decline—measurable on neuropsychological tests—but not reversal of existing damage. Many patients and families ask: if my loved one is slowing their mental decline by 35% over 18 months, is that worth monthly injections and serious risks? The EMA committee decided the answer for Europe is often “no,” while the FDA has been more willing to let individual patients and doctors make that choice.
The Path Forward for Patients and Families in Europe—What Treatment Options Remain?
For patients and families in Europe facing an Alzheimer’s diagnosis, the delayed or rejected drug approvals feel like a setback, and in many respects, it is one. Lecanemab (Leqembi) remains the closest thing to an approved anti-amyloid option, though even that approval remains conditional and under additional scrutiny as of early 2025. Where lecanemab becomes available in Europe, it is offered as a weekly infusion lasting one hour, requiring specialized infusion centers and regular MRI monitoring. This is a practical and financial burden that not all patients or healthcare systems can accommodate. Many European patients currently rely on cholinesterase inhibitors like donepezil or rivastigmine, which modestly slow cognitive decline but work through a different mechanism—supporting remaining acetylcholine in the brain rather than clearing amyloid.
These older drugs have been standard care for two decades and remain the most widely prescribed Alzheimer’s medications outside the United States. For mild cognitive impairment or early Alzheimer’s, these medications offer a safer alternative to the newer infusion-based anti-amyloid therapies, though with more modest effects. Lifestyle interventions—cognitive stimulation, physical exercise, Mediterranean diet, social engagement, sleep optimization, and management of cardiovascular risk factors—remain evidence-based approaches that regulators and clinicians alike recognize as foundational. The practical implication is that European patients and families cannot expect a “magic bullet” drug to emerge soon. Instead, they are working with neurologists to optimize what is available: established medications, lifestyle changes, cognitive rehabilitation, and potentially, access to lecanemab if their healthcare system and individual circumstances permit. Some patients may choose to travel to the United States or other countries where newer drugs are approved, though this is feasible only for a small minority with resources and mobility.
How Regulatory Delays Affect Clinical Practice and Treatment Planning
When a drug is rejected by European regulators, the impact ripples through clinical practice. Neurologists must counsel patients differently in Europe than in the United States. A clinician in Germany or France cannot offer Kisunla, even to patients who might request it based on Internet searches or conversations with international contacts. This creates frustration and a sense of being left behind, particularly in border regions where patients might expect parity of access with neighboring countries that eventually approve drugs. The delays also affect clinical trial design and pharmaceutical development. Companies may decide that the European market is too uncertain to warrant the investment in large, lengthy trials. Smaller companies like Anavex may withdraw rather than navigate the EMA’s rigorous review process.
This shift in investment patterns means fewer drugs move through European regulatory pipelines, further limiting future options. A cautious regulatory stance, while protective in the short term, can paradoxically reduce access over time if it discourages innovation and development. Healthcare systems must also plan differently. If regulatory approval remains uncertain, hospital systems cannot fund infusion centers or train staff for specific protocols. Patients cannot realistically access treatments that may be approved tomorrow but are not approved today. The 67-day timeline for the European Commission’s decision on Kisunla means another two months of planning limbo for healthcare administrators in every European country. This bureaucratic delay, while ensuring careful review, is experienced by patients as a missed opportunity to access a new treatment option.
What About Other Alzheimer’s Drugs in the Development Pipeline?
Beyond Kisunla and blarcamesine, numerous other investigational Alzheimer’s drugs are in development or undergoing regulatory review across the world. Donanemab variants, tau-targeting therapies, and combination approaches are all being studied. However, the European regulatory environment presents a cautionary tale: even drugs that show promise in trials and receive approval or recommendation elsewhere may face significant barriers in Europe. Companies must weigh the costs of navigating the EMA’s demanding approval process against uncertain prospects of eventual market access and reimbursement.
Tau-targeting drugs represent an alternative mechanism being explored, based on the observation that tau tangles, not just amyloid plaques, drive neurodegeneration in Alzheimer’s disease. These drugs have not yet faced the same degree of regulatory rejection in Europe, partly because they are earlier in development. However, any drug targeting brain pathology carries potential for ARIA and other neurological side effects. The EMA’s experience with Kisunla and lecanemab will likely shape how European regulators approach tau-targeted therapies, potentially applying the same cautious standard and requesting similar levels of safety data.
Looking Forward—What the European Regulatory Delays Mean for the Future of Dementia Care
The divergence between European and U.S. regulatory approaches to Alzheimer’s drugs will likely persist and possibly widen. The EMA’s caution reflects genuine debate within European medical communities about whether the benefits of anti-amyloid drugs justify their risks and costs. This is a legitimate regulatory stance, not a bureaucratic error, though it will frustrate patients and families hoping for access to newer treatments.
Over the next few years, European regulators will likely become more comfortable with lecanemab as safety data accumulates, but the rejection of Kisunla suggests that not all anti-amyloid drugs will eventually be approved, even in Europe. The future of Alzheimer’s treatment in Europe may instead emphasize combination approaches, lifestyle optimization, and earlier diagnosis. Some researchers and clinicians argue that European healthcare systems should focus on identifying people with preclinical Alzheimer’s disease—amyloid in the brain but no cognitive symptoms yet—and enrolling them in lifestyle intervention programs before any drug therapy is necessary. This approach aligns with European regulatory caution and the reality that no current drug completely stops or reverses Alzheimer’s disease. As new drugs continue to emerge, the regulatory process will likely remain stringent in Europe, creating ongoing delays relative to the United States but also potentially protecting patients from premature exposure to treatments with uncertain long-term safety profiles.
Conclusion
European market access delays for investigational Alzheimer’s drugs reflect a regulatory philosophy that prioritizes safety and evidence over rapid approval. The withdrawal of blarcamesine and the non-recommendation of Kisunla are specific, high-profile instances of this cautious approach, but they signal a broader pattern. Lecanemab’s complicated path through European approval—initially rejected, later conditionally recommended, then subjected to additional safety review—illustrates the complexity of bringing new Alzheimer’s treatments to European patients. For families and patients in Europe, this means fewer new treatment options available, at least in the near term, and reliance on established medications and lifestyle interventions.
The path forward requires realistic expectations. New Alzheimer’s drugs will likely continue to be approved in the United States before, and sometimes instead of, reaching European patients. Healthcare systems and clinicians must plan with that reality in mind, optimizing available treatments and preparing for the possibility that some promising drugs may never become available in Europe. Patients can work with their neurologists to maximize current care strategies while staying informed about regulatory progress on drugs in the pipeline. The regulatory delays are frustrating, but they also represent a deliberate choice by European regulators to demand stronger evidence that benefits outweigh serious risks—a philosophy that will shape Alzheimer’s treatment in Europe for years to come.
You Might Also Like
- University Researchers Push Boundaries of Alzheimer’s Drug Discovery
- Support Networks Help Alzheimer’s Families Access Resources and Care
- Failed Drug Trial Shifts Focus in Alzheimer’s Research Strategy
For more, see Alzheimer’s Association — clinical trials.
